Neonatal therapy after maternal central neurotropic drug exposure-a retrospective cohort study (2024)

Abstract

OBJECTIVE: Evaluation of neonatal morbidity after maternal central neurotropic drug exposure. METHODS: Retrospective single-center level-III neonatology cohort analysis of neonates after CND from 2018 to 2021. Control group of neonates born to mothers without CND cared for at the maternity ward. RESULTS: Significantly more frequent therapy need of neonates with CND [OR 23 (95% CI: 7.8-62); RR 14 (95% CI: 5.4-37); p < 0.01]. Neonates after CND had lower Apgar-scores LM 1 [CND 8.1; CG 8.6; p < 0.05]; LM 5 [CND 9; CG 9.7; p < 0.01]; LM 10 [CND 9.6; CG 9.9; p < 0.05]. The first symptom occurred in 95.35% within 24 h (mean: 3.3 h). CND group showed significantly more often preterm delivery [OR 3.5; RR 3.2; p < 0.05], and especially cumulative multiple symptoms [OR 9.4; RR 6.6; p < 0.01] but no correlation to multiple maternal medication use (p = 0.3). CONCLUSIONS: Neonates exposed to CND are at increased risk for postnatal therapy, often due to multiple symptoms. Neonates should be continuously monitored for at least 24 h.

Original languageEnglish
Pages (from-to)2356038
Number of pages1
JournalJournal of Maternal-Fetal and Neonatal Medicine
Volume37
Issue number1
DOIs
StatePublished - 1 Dec 2024
Externally publishedYes

Keywords

  • antidepressants
  • fetal exposure
  • maternal central neurotropic drug exposure
  • Neonatal therapy
  • retrospective cohort study

Access to Document

Other files and links

Fingerprint

Dive into the research topics of 'Neonatal therapy after maternal central neurotropic drug exposure-a retrospective cohort study'. Together they form a unique fingerprint.

View full fingerprint

Cite this

  • APA
  • Author
  • BIBTEX
  • Harvard
  • Standard
  • RIS
  • Vancouver

Wecker, S. N., Dammert, A. S., Scholz, C., Krüger, M., Hauer, J., & Brickmann, C. (2024). Neonatal therapy after maternal central neurotropic drug exposure-a retrospective cohort study. Journal of Maternal-Fetal and Neonatal Medicine, 37(1), 2356038. https://doi.org/10.1080/14767058.2024.2356038

Wecker, Sabrina Nicole ; Dammert, Ann Sophie ; Scholz, Christoph et al. / Neonatal therapy after maternal central neurotropic drug exposure-a retrospective cohort study. In: Journal of Maternal-Fetal and Neonatal Medicine. 2024 ; Vol. 37, No. 1. pp. 2356038.

@article{24ef9cc2fc6346d2a982d295b9eee5ef,

title = "Neonatal therapy after maternal central neurotropic drug exposure-a retrospective cohort study",

abstract = "OBJECTIVE: Evaluation of neonatal morbidity after maternal central neurotropic drug exposure. METHODS: Retrospective single-center level-III neonatology cohort analysis of neonates after CND from 2018 to 2021. Control group of neonates born to mothers without CND cared for at the maternity ward. RESULTS: Significantly more frequent therapy need of neonates with CND [OR 23 (95% CI: 7.8-62); RR 14 (95% CI: 5.4-37); p < 0.01]. Neonates after CND had lower Apgar-scores LM 1 [CND 8.1; CG 8.6; p < 0.05]; LM 5 [CND 9; CG 9.7; p < 0.01]; LM 10 [CND 9.6; CG 9.9; p < 0.05]. The first symptom occurred in 95.35% within 24 h (mean: 3.3 h). CND group showed significantly more often preterm delivery [OR 3.5; RR 3.2; p < 0.05], and especially cumulative multiple symptoms [OR 9.4; RR 6.6; p < 0.01] but no correlation to multiple maternal medication use (p = 0.3). CONCLUSIONS: Neonates exposed to CND are at increased risk for postnatal therapy, often due to multiple symptoms. Neonates should be continuously monitored for at least 24 h.",

keywords = "antidepressants, fetal exposure, maternal central neurotropic drug exposure, Neonatal therapy, retrospective cohort study",

author = "Wecker, {Sabrina Nicole} and Dammert, {Ann Sophie} and Christoph Scholz and Marcus Kr{\"u}ger and Julia Hauer and Christian Brickmann",

year = "2024",

month = dec,

day = "1",

doi = "10.1080/14767058.2024.2356038",

language = "English",

volume = "37",

pages = "2356038",

journal = "Journal of Maternal-Fetal and Neonatal Medicine",

issn = "1476-7058",

publisher = "Informa Healthcare",

number = "1",

}

Wecker, SN, Dammert, AS, Scholz, C, Krüger, M, Hauer, J & Brickmann, C 2024, 'Neonatal therapy after maternal central neurotropic drug exposure-a retrospective cohort study', Journal of Maternal-Fetal and Neonatal Medicine, vol. 37, no. 1, pp. 2356038. https://doi.org/10.1080/14767058.2024.2356038

Neonatal therapy after maternal central neurotropic drug exposure-a retrospective cohort study. / Wecker, Sabrina Nicole; Dammert, Ann Sophie; Scholz, Christoph et al.
In: Journal of Maternal-Fetal and Neonatal Medicine, Vol. 37, No. 1, 01.12.2024, p. 2356038.

Research output: Contribution to journalArticlepeer-review

TY - JOUR

T1 - Neonatal therapy after maternal central neurotropic drug exposure-a retrospective cohort study

AU - Wecker, Sabrina Nicole

AU - Dammert, Ann Sophie

AU - Scholz, Christoph

AU - Krüger, Marcus

AU - Hauer, Julia

AU - Brickmann, Christian

PY - 2024/12/1

Y1 - 2024/12/1

N2 - OBJECTIVE: Evaluation of neonatal morbidity after maternal central neurotropic drug exposure. METHODS: Retrospective single-center level-III neonatology cohort analysis of neonates after CND from 2018 to 2021. Control group of neonates born to mothers without CND cared for at the maternity ward. RESULTS: Significantly more frequent therapy need of neonates with CND [OR 23 (95% CI: 7.8-62); RR 14 (95% CI: 5.4-37); p < 0.01]. Neonates after CND had lower Apgar-scores LM 1 [CND 8.1; CG 8.6; p < 0.05]; LM 5 [CND 9; CG 9.7; p < 0.01]; LM 10 [CND 9.6; CG 9.9; p < 0.05]. The first symptom occurred in 95.35% within 24 h (mean: 3.3 h). CND group showed significantly more often preterm delivery [OR 3.5; RR 3.2; p < 0.05], and especially cumulative multiple symptoms [OR 9.4; RR 6.6; p < 0.01] but no correlation to multiple maternal medication use (p = 0.3). CONCLUSIONS: Neonates exposed to CND are at increased risk for postnatal therapy, often due to multiple symptoms. Neonates should be continuously monitored for at least 24 h.

AB - OBJECTIVE: Evaluation of neonatal morbidity after maternal central neurotropic drug exposure. METHODS: Retrospective single-center level-III neonatology cohort analysis of neonates after CND from 2018 to 2021. Control group of neonates born to mothers without CND cared for at the maternity ward. RESULTS: Significantly more frequent therapy need of neonates with CND [OR 23 (95% CI: 7.8-62); RR 14 (95% CI: 5.4-37); p < 0.01]. Neonates after CND had lower Apgar-scores LM 1 [CND 8.1; CG 8.6; p < 0.05]; LM 5 [CND 9; CG 9.7; p < 0.01]; LM 10 [CND 9.6; CG 9.9; p < 0.05]. The first symptom occurred in 95.35% within 24 h (mean: 3.3 h). CND group showed significantly more often preterm delivery [OR 3.5; RR 3.2; p < 0.05], and especially cumulative multiple symptoms [OR 9.4; RR 6.6; p < 0.01] but no correlation to multiple maternal medication use (p = 0.3). CONCLUSIONS: Neonates exposed to CND are at increased risk for postnatal therapy, often due to multiple symptoms. Neonates should be continuously monitored for at least 24 h.

KW - antidepressants

KW - fetal exposure

KW - maternal central neurotropic drug exposure

KW - Neonatal therapy

KW - retrospective cohort study

UR - http://www.scopus.com/inward/record.url?scp=85194995153&partnerID=8YFLogxK

U2 - 10.1080/14767058.2024.2356038

DO - 10.1080/14767058.2024.2356038

M3 - Article

C2 - 38830822

AN - SCOPUS:85194995153

SN - 1476-7058

VL - 37

SP - 2356038

JO - Journal of Maternal-Fetal and Neonatal Medicine

JF - Journal of Maternal-Fetal and Neonatal Medicine

IS - 1

ER -

Wecker SN, Dammert AS, Scholz C, Krüger M, Hauer J, Brickmann C. Neonatal therapy after maternal central neurotropic drug exposure-a retrospective cohort study. Journal of Maternal-Fetal and Neonatal Medicine. 2024 Dec 1;37(1):2356038. doi: 10.1080/14767058.2024.2356038

Neonatal therapy after maternal central neurotropic drug exposure-a retrospective cohort study (2024)

References

Top Articles
Latest Posts
Article information

Author: Kerri Lueilwitz

Last Updated:

Views: 6473

Rating: 4.7 / 5 (47 voted)

Reviews: 94% of readers found this page helpful

Author information

Name: Kerri Lueilwitz

Birthday: 1992-10-31

Address: Suite 878 3699 Chantelle Roads, Colebury, NC 68599

Phone: +6111989609516

Job: Chief Farming Manager

Hobby: Mycology, Stone skipping, Dowsing, Whittling, Taxidermy, Sand art, Roller skating

Introduction: My name is Kerri Lueilwitz, I am a courageous, gentle, quaint, thankful, outstanding, brave, vast person who loves writing and wants to share my knowledge and understanding with you.